What is the 13F Pro Quality Score for SPRO?

13F Pro ranks Spero Therapeutics, Inc. (SPRO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SPRO's current score at https://13fpro.ai/company/SPRO (free sign-up required for the full ranking).

Which hedge funds own the most SPRO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SPRO include GSK plc, PFIZER, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SPRO as soon as new 13F filings post.

Where does 13F Pro source SPRO data?

All Spero Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Spero Therapeutics, Inc. files with the SEC under CIK 1701108. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SPRO in?

Spero Therapeutics, Inc. (SPRO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SPRO's revenue?

Per Spero Therapeutics, Inc.'s latest 10-Q filed with the SEC on 2026-08-12, the biggest revenue drivers are: Collaboration revenue - related party (GSK) ($0, -$11.8M YoY); Grant revenue (BARDA contract, tebipenem pivoxil) ($0, -$2.4M YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/SPRO.

What are SPRO's largest expenses?

Spero Therapeutics, Inc.'s latest 10-Q reports these as the largest expense items: General and administrative ($6.5M, +$0.6M YoY); Research and development ($3.4M, -$7.2M YoY); Professional and consultant fees (within G&A) ($4.2M, +$2.2M YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is SPRO research updated on 13F Pro?

SPRO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Spero Therapeutics, Inc.(SPRO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1701108 SPRO stock profile & AI dashboard →

13F Pro Quality Score

57.6/100

Rank #1,087 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

22.1/100

Profitability

80.0/100

Balance Sheet

90.2/100

Earnings Quality

87.5/100

Free Cash Flow

91.8/100

Institutional Flow

52.1/100

Revenue Scale

8.2/100

Dilution Risk

21.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SPRO Scores 58/100

exact factor attribution · 2026-09-11

SPRO's composite is driven by free cash flow and profitability, held back by scale and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+6.3 pts

92th pct

Profitability

+4.5 pts

80th pct

Capital efficiency

+4.0 pts

90th pct

Earnings quality

+3.8 pts

88th pct

Earnings growth

+2.3 pts

95th pct

Institutional flow

+0.1 pts

52th pct

Shareholder dilution

-1.4 pts

22th pct

Revenue growth

-5.6 pts

22th pct

Scale

-6.3 pts

8th pct

Latest change (2026-08-12): 20 → 25 · ↓ Dilution 22→6

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SPRO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Spero Therapeutics, Inc. (SPRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRO at 57.6/100 on a 32-signal composite quality model, placing it at rank #1,087 of 2,962 stocks — the top half of the AI-ranked universe. SPRO scores in the top quartile across free cash flow (91.8), balance sheet strength (90.2), earnings quality (87.5). Areas of concern include revenue scale (8.2) and revenue growth (22.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of SPRO by reported 13-F value include GSK plc, PFIZER, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SPRO trades on the Nasdaq exchange and files with the SEC under CIK 1701108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Spero Therapeutics, Inc. directly from SEC EDGAR. Spero Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 72 since 2021, currently 57.6 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Spero Therapeutics, Inc.

Quirks, history, and lore behind SPRO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · focused on serious bacterial infections · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
A small-cap clinical-stage company with limited commercial revenue — the kind of balance sheet where every pipeline update moves the stock by double digits.
3
The History
Founded in the mid-2010s, it was built around tackling antimicrobial resistance — one of medicine's most stubborn and underfunded problems.
4
The Secret
Its pipeline targets multidrug-resistant (MDR) pathogens, the bacteria that laugh at standard antibiotics — a niche most big pharma companies have largely abandoned.
5
The Lore
The company's name is derived from the Latin word for "hope" — fitting for a firm betting that the world will finally pay attention to the antibiotic resistance crisis.
6
The Giveaway
Ticker SPRO, named for hope, fighting superbugs from Cambridge — this is Spero Therapeutics.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SPRO's Business? Latest 10-Q Breakdown

✓ 12/12 datapoints verified

AI-extracted from Spero Therapeutics, Inc.'s 10-Q filed 2026-08-12 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Spero recorded no revenue in Q2 2026, down $14.2M from a year earlier, and a $9.6M net loss as GSK collaboration and BARDA grant revenue ceased.

Biggest Revenue Drivers

Collaboration revenue - related party (GSK)$0-$11.8M YoY

Decrease "primarily related to the achievement of remaining development milestone activities under the agreement"

Grant revenue (BARDA contract, tebipenem pivoxil)$0-$2.4M YoY

Decrease "primarily due to a decrease of $2.4 million of committed funds remaining available under our BARDA contract"

Biggest Revenue Drivers

Total revenue: $0-$14.2M YoY

Collaboration revenue - related party (GSK)$0-$11.8M YoY

Decrease "primarily related to the achievement of remaining development milestone activities under the agreement"

Grant revenue (BARDA contract, tebipenem pivoxil)$0-$2.4M YoY

Decrease "primarily due to a decrease of $2.4 million of committed funds remaining available under our BARDA contract"

Largest Expense Items

General and administrative$6.5M+$0.6M YoY

Professional and consultant fees rose $2.2M on business development, legal and consulting; personnel costs fell $1.6M on lower headcount

Research and development$3.4M-$7.2M YoY

Tebipenem pivoxil direct costs fell $5.4M on decreased Phase 3 PIVOT-PO activity; personnel costs fell $1.3M

Professional and consultant fees (within G&A)$4.2M+$2.2M YoY

Increase in business development, legal and consulting expenses in the quarter

Margins: No margin discussion; the filing reports a $9.9M loss from operations versus $2.4M a year ago, driven by revenue falling to zero against $9.9M of operating expenses.

Watch Items from the Filing

BARDA contract mutually terminated July 6, 2026 with all remaining funds deobligated; no further BARDA funding, after $65.1M of $65.6M committed was already recognized.
July 2026 $105.0M HCRx royalty financing: notes accrue 10% interest and Spero retains only 35% of GSK Proceeds arising after the notes are repaid.
Innovent license for SP001 obligates a $35.0M upfront payment plus up to ~$1.05 billion in milestones and high single-digit to mid-teen royalties.
Remaining GSK upside: $101.0M of commercial milestones and $225.0M of sales milestones, with royalties of 1% on annual net sales up to $750.0M.
Cash of $50.8M plus royalty financing proceeds funds operations into the second half of 2029; accumulated deficit is $467.8M with no product sales revenue.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-9.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+39.2% YoY

$66.8MFY 2025

FY22 $53.5MFY23 $103.8MFY24 $48.0MFY25 $66.8M

Net Income

+112.5% YoY

$8.6MFY 2025

FY22 —FY23 $22.8MFY24 $-68.6MFY25 $8.6M

Operating Income

+108.6% YoY

$6.3MFY 2025

FY22 $-42.2MFY23 $21.5MFY24 $-73.4MFY25 $6.3M

EPS (Diluted)

+111.8% YoY

$0.15FY 2025

FY22 $-1.23FY23 $0.43FY24 $-1.27FY25 $0.15

Total Assets

-37.7% YoY

$68.9MFY 2025

FY22 $124.8MFY23 $182.4MFY24 $110.5MFY25 $68.9M

Op. Cash Flow

+46.2% YoY

$-12.6MFY 2025

FY22 $-7.7MFY23 $-33.0MFY24 $-23.4MFY25 $-12.6M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$66.8M +39.2%	$48.0M -53.8%	$103.8M +94.0%	$53.5M +193.1%	$18.3M +95.7%	$9.3M
Net Income	$8.6M +112.5%	$-68.6M -400.6%	$22.8M	—	$-89.8M -14.7%	$-78.3M
Operating Income	$6.3M +108.6%	$-73.4M -441.5%	$21.5M +150.9%	$-42.2M +52.0%	$-88.0M -11.2%	$-79.1M
EPS (Diluted)	$0.15 +111.8%	$-1.27 -395.3%	$0.43 +135.0%	$-1.23 +57.7%	$-2.91	—
Total Assets	$68.9M -37.7%	$110.5M -39.4%	$182.4M +46.1%	$124.8M -27.0%	$171.1M +11.5%	$153.5M
Operating Cash Flow	$-12.6M +46.2%	$-23.4M +28.9%	$-33.0M -326.8%	$-7.7M +88.0%	$-64.3M +25.1%	$-85.9M
Free Cash Flow	—	—	—	—	—	$-86.0M

Get alerted when SPRO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Spero Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SPRO

GSK plc
$20.3M9,190,606 sh
PFIZER INC
$5.3M2,362,348 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.5M2,036,226 sh
RENAISSANCE TECHNOLOGIES LLC
$2.1M947,904 sh
Alphabet Inc.
$2.0M889,979 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.7M759,290 sh
BlackRock, Inc.
$1.3M594,404 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3M566,329 sh
RAYMOND JAMES FINANCIAL INC
$1.2M521,705 sh
TWO SIGMA INVESTMENTS, LP
$846.0K382,814 sh

Fund	Value	Shares
GSK plc	$20.3M	9,190,606
PFIZER INC	$5.3M	2,362,348
VANGUARD CAPITAL MANAGEMENT LLC	$4.5M	2,036,226
RENAISSANCE TECHNOLOGIES LLC	$2.1M	947,904
Alphabet Inc.	$2.0M	889,979
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.7M	759,290
BlackRock, Inc.	$1.3M	594,404
GEODE CAPITAL MANAGEMENT, LLC	$1.3M	566,329
RAYMOND JAMES FINANCIAL INC	$1.2M	521,705
TWO SIGMA INVESTMENTS, LP	$846.0K	382,814

Companies Similar to SPRO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TBPH

Theravance Biopharma, Inc.

AI score

Similar quality profile · 1 shared holders

Susquehanna Portfolio Strategies, LLC

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile

CRMD

CorMedix Inc.

AI score

Similar quality profile

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile

BLFS

BIOLIFE SOLUTIONS INC

AI score

Similar quality profile

FBIO

Fortress Biotech, Inc.

AI score

Similar quality profile

IRMD

IRADIMED CORP

AI score

Similar quality profile · 1 shared holders

Susquehanna Portfolio Strategies, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SPRO on your watchlist

Track score changes the day Spero Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SPRO a good stock to buy?

13F Pro's AI-powered analysis of Spero Therapeutics, Inc. (SPRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SPRO are available on the SPRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SPRO is classified as a small company.

Which hedge funds own SPRO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SPRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Spero Therapeutics, Inc.'s investment landscape.